Alkermes drug helped cut heavy drinking

Alkermes announced that updated data from its Phase III research on an experimental drug for alcoholism showed that patients switching to the drug from a placebo experienced a decline in heavy drinking. The drug developer had earlier said that the first six months of the study showed that the median number of days of heavy drinking among patients taking Vivitrex fell to three from 19 per month. This new data followed the patients over the following 12 months. At the end of that period patients reported that they had a median 1.6 days of heavy drinking per month. Heavy drinking was defined as five or more drinks per day for a man, four or more for a woman.

- read this story from TheStreet.com for more on the trial

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.